For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
TCPCL is the largest and only commercial manufacturer of SDAs for zeolites in India
Subscribe To Our Newsletter & Stay Updated
